Compare GPRE & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GPRE | AKBA |
|---|---|---|
| Founded | 2004 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 631.4M | 729.1M |
| IPO Year | N/A | 2014 |
| Metric | GPRE | AKBA |
|---|---|---|
| Price | $10.25 | $1.58 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 6 |
| Target Price | ★ $8.69 | $6.25 |
| AVG Volume (30 Days) | 1.7M | ★ 5.0M |
| Earning Date | 11-05-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,246,853,000.00 | $225,071,000.00 |
| Revenue This Year | N/A | $52.38 |
| Revenue Next Year | N/A | $22.45 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 32.49 |
| 52 Week Low | $3.14 | $1.45 |
| 52 Week High | $12.31 | $4.08 |
| Indicator | GPRE | AKBA |
|---|---|---|
| Relative Strength Index (RSI) | 51.82 | 36.99 |
| Support Level | $9.53 | $1.45 |
| Resistance Level | $10.43 | $1.63 |
| Average True Range (ATR) | 0.55 | 0.10 |
| MACD | 0.03 | 0.03 |
| Stochastic Oscillator | 73.61 | 39.74 |
Green Plains Inc manufactures and sells ethanol and ethanol byproducts in two segments based on function. The ethanol production segment, which generates the majority of revenue, includes the production of ethanol, distillers grains, Ultra-High Protein and renewable corn oil. The agribusiness and energy services segment includes grain handling and storage, commodity marketing and merchant trading for company-produced and third-party ethanol, distillers grains, Ultra-High Protein, renewable corn oil, natural gas and other commodities.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.